Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Depreciation and Depletion (2020 - 2026)

Cytek Biosciences filings provide 6 years of Depreciation and Depletion readings, the most recent being $1.0 million for Q4 2025.

  • On a quarterly basis, Depreciation and Depletion rose 11.11% to $1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.9 million, a 11.43% increase, with the full-year FY2025 number at $3.9 million, up 11.43% from a year prior.
  • Depreciation and Depletion hit $1.0 million in Q4 2025 for Cytek Biosciences, roughly flat from $1.0 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $1.0 million in Q2 2025 to a low of $167000.0 in Q1 2021.
  • Median Depreciation and Depletion over the past 5 years was $700000.0 (2023), compared with a mean of $635250.0.
  • Biggest five-year swings in Depreciation and Depletion: soared 191.6% in 2021 and later changed 0.0% in 2024.
  • Cytek Biosciences' Depreciation and Depletion stood at $347000.0 in 2021, then skyrocketed by 44.09% to $500000.0 in 2022, then surged by 60.0% to $800000.0 in 2023, then grew by 12.5% to $900000.0 in 2024, then increased by 11.11% to $1.0 million in 2025.
  • The last three reported values for Depreciation and Depletion were $1.0 million (Q4 2025), $1.0 million (Q3 2025), and $1.0 million (Q2 2025) per Business Quant data.